Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial

BACKGROUND: Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of stages II and III triple-negative breast cancer (TNBC). This study aims to evaluate if the addition of carboplatin to NACT is associated with an increase in the pathological complete response (pCR) rates in TNBC. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: de Pádua Souza, Cristiano, Carneiro, Ana Suellen Barroso, de Oliveira Lessa, Ana Cecília, Lacerda, Domício Carvalho, Paiva, Carlos Eduardo, Zorzetto, Marina Moreira Costa, de Freitas, Ana Julia Aguiar, Santana, Iara Viana Vidigal, de Oliveira, Marco Antonio, Palmero, Edenir Inêz, Marques, Márcia Maria Chiquitelli, Reinert, Tomás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504209/
https://www.ncbi.nlm.nih.gov/pubmed/37578666
http://dx.doi.org/10.1007/s10549-023-07011-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504209/
https://www.ncbi.nlm.nih.gov/pubmed/37578666
http://dx.doi.org/10.1007/s10549-023-07011-0

Ejemplares similares